NCT06551129 · Bristol-Myers Squibb
Real-world Patient Reported Outcomes Among Patients Treated With Camzyos
(COMPASS-HCM)
What this study is about
This real-world study will assess changes in health status among participants with symptomatic obstructive hypertrophic cardiomyopathy who are treated with mavacamten in the real world.
View original scientific description
This real-world study will assess changes in health status among participants with symptomatic obstructive hypertrophic cardiomyopathy who are treated with mavacamten in the real world.
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Participants ≥18 years of age.
- Participants who are prescribed mavacamten for obstructive hypertrophic cardiomyopathy
- Provided informed consent to participate in the study
Exclusion criteria
- Previously or currently enrolled in clinical trials for any cardiac myosin inhibitors
- Treated for \>7 days with mavacamten by the day of completing the baseline survey
- Enrolled in any clinical trials at the time of or within the six-month period prior to the screening
- Had heart attack requiring coronary artery bypass grafting within the three-month period prior to the screening
- Had stroke or transient ischemic attack within the six-month period prior to the screening
- Had moderate-to-severe lung disease which impacted the ability to perform daily activities of living and ability to breathe
- Had major lung (thoracic) or heart (cardiac) surgery within the six-month period prior to the screening
- Scheduled for a major surgery for the next three months, such as joint surgeries including hip replacement, abdominal surgeries, lung surgeries, heart surgeries, eye surgeries, brain surgeries, and any other major surgeries that require general anesthesia and at least an overnight hospital stay
- Hospitalized requiring an overnight stay at the time of or within the two-week period prior to the screening
Where
- Boston, Massachusetts
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Nov 7, 2024 · Source of record for eligibility and locations